FGFR3, fibroblast growth factor receptor 3, 2261

N. diseases: 558; N. variants: 42
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.700 GeneticVariation disease BEFREE We compared immunoglobulin heavy chain gene (IGH) signal patterns in multiple myeloma (MM) using the FGFR3-IGH and the IGH break-apart probes to facilitate their understanding and analysis. 29040969 2018
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.700 Biomarker disease BEFREE Protein Expression for Novel Prognostic Markers (Cyclins D1, D2, D3, B1, B2, ITGβ7, FGFR3, PAX5) Correlate With Previously Reported Gene Expression Profile Patterns in Plasma Cell Myeloma. 25265432 2016
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.700 GeneticVariation disease CLINVAR Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 26619011 2016
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.700 GeneticVariation disease BEFREE Approximately 15% of patients with multiple myeloma (MM) exhibit a t(4;14) translocation, which often results in constitutive activation of the receptor tyrosine kinase (RTK) fibroblast growth factor receptor 3 (FGFR3). 25402977 2016
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.700 AlteredExpression disease BEFREE MS analysis of protein-phosphotyrosine in multiple myeloma cells revealed a prevalent phosphorylated motif, D/EYYR/K, derived from the kinase domain activation loops of tyrosine kinases including FGFR3 corresponding to a recognition sequence of protein-tyrosine phosphatase PTPN1. 25311528 2015
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.700 PosttranslationalModification disease BEFREE Fibroblast growth factor receptor 3 interacts with and activates TGFβ-activated kinase 1 tyrosine phosphorylation and NFκB signaling in multiple myeloma and bladder cancer. 24466111 2014
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.700 AlteredExpression disease BEFREE We found that target genes of the most differentially expressed miRNAs are directly involved in the pathogenesis of MM; specifically, the inhibition of hsa-miR-425, hsa-miR-152 and hsa-miR-24, which are all downregulated in h-MM, leads to the overexpression of CCND1, TACC3, MAFB, FGFR3 and MYC, which are the also the oncogenes upregulated by the most frequent IgH chromosomal translocations occurring in nh-MM. 23174883 2013
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.700 AlteredExpression disease BEFREE Thalidomide consolidation improves progression-free survival in myeloma with normal but not up-regulated expression of fibroblast growth factor receptor 3: analysis from the Australasian Leukaemia and Lymphoma Group MM6 clinical trial. 22329352 2013
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.700 GeneticVariation disease BEFREE Cases of multiple myeloma and monoclonal gammopathy of undetermined significance frequently showed different but related cytogenetic profiles when other cytogenetic alterations such as deletions/gains of the immunoglobulin heavy chain or the fibroblast growth factor receptor 3 were additionally considered. 22929983 2013
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.700 GeneticVariation disease BEFREE Among recurrent IGH translocations in MM, the frequency of t(4;14) (IGH and FGFR3) or t(11;14) (IGH and CCND1) is greater than the frequency of t(14;16) (IGH and MAF). 23460268 2013
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.700 Biomarker disease BEFREE As a part of these translational efforts, novel drugs that inhibit oncogenic proteins overexpressed in defined molecular subgroups of the disease, such as FGFR3 and MMSET in t(4;14) MM, are currently being developed. 23233602 2013
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.700 Biomarker disease BEFREE Ribosomal protein metallopanstimulin-1 impairs multiple myeloma CAG cells growth and inhibits fibroblast growth factor receptor 3. 21889435 2012
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.700 Biomarker disease CTD_human Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. 21936542 2012
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.700 GeneticVariation disease BEFREE From a clinical standpoint, it is critical to identify MM patients carrying the t(4;14) translocation, which is present in 15% of myelomas and is associated with dysregulation of WHSC1/MMSET and often FGFR3. 22160056 2012
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.700 AlteredExpression disease BEFREE These data demonstrate that PD173074 and sunitinib are inhibitors of FGFR3 in MM cell lines, and that sunitinib has in vivo activity in a human MM tumour xenograft model. 21316102 2011
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.700 GeneticVariation disease BEFREE The ectopically expressed fibroblast growth factor receptor 3 (FGFR3) and its constitutively active mutations have been detected in patients with multiple myeloma (MM). 21273588 2011
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.700 Biomarker disease BEFREE A t(4;14)/IGH-FGFR3 was detected in 28 PCM (11.1%) and 5 MGUS (1.9%; P < 0.001). 21156229 2011
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.700 Biomarker disease BEFREE In samples from all four patients with multiple myeloma and from two of the three with monoclonal gammopathy of undetermined significance, we identified memory B cells expressing multiple myeloma-specific oncogenes (FGFR3; IGH-MMSET; CCND1 high) dysregulated by an IGH translocation in the respective tumor plasma cells. 20511669 2011
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.700 Biomarker disease BEFREE Similarly, NF449 antagonized FGFR3 action in the multiple myeloma cell lines OPM2 and KMS11, as evidenced by NF449-mediated reversal of ERK MAPK activation and transcript accumulation of CCL3 and CCL4 chemokines, both of which are induced by FGFR3 activation. 20439987 2010
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.700 AlteredExpression disease BEFREE Multiple myeloma phosphotyrosine proteomic profile associated with FGFR3 expression, ligand activation, and drug inhibition. 19901323 2010
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.700 AlteredExpression disease BEFREE This suggests that dysregulated FGFR3 expression is likely to be essential at least for the early stages of pathogenesis of MM tumors that have a t(4;14) translocation. 20393505 2010
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.700 GeneticVariation disease BEFREE Reciprocal IGH/14q32 translocations are detectable in 55-70% of patients with plasma cell myeloma; e.g., the adverse t(4;14)(p16;q32) fusing the IGH and FGFR3 genes (immunoglobulin heavy chain/fibroblast growth factor receptor 3). 20620602 2010
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.700 AlteredExpression disease BEFREE Bortezomib therapeutic effect is associated with expression of FGFR3 in multiple myeloma cells. 19331127 2009
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.700 AlteredExpression disease BEFREE FGFR3 is expressed and is important for survival in INA-6, a human myeloma cell line without a t(4;14). 19594619 2009
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.700 Biomarker disease BEFREE Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma. 19147757 2009